Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 28;13(3):343-358.
doi: 10.3390/neurolint13030035.

Paliperidone to Treat Psychotic Disorders

Hormazd D Minwalla  1 , Peter Wrzesinski  1 , Allison Desforges  2 , Joshua Caskey  2 , Brittany Wagner  2 , Patrick Ingraffia  2 , James C Patterson 2nd  1 , Amber N Edinoff  1 , Adam M Kaye  3 , Alan D Kaye  4 , Omar Viswanath  4   5   6   7 , Ivan Urits  4   8
Affiliations
Review

Paliperidone to Treat Psychotic Disorders

Hormazd D Minwalla et al. Neurol Int. .

Abstract

Purpose of review: This is a comprehensive review of the literature regarding the use of paliperidone in the treatment of schizophrenia and schizoaffective disorder. It covers the background and presentation of schizophrenia and schizoaffective disorder, as well as the mechanism of action and drug information for paliperidone. It covers the existing evidence of the use of paliperidone for the treatment of schizophrenia and schizoaffective disorder.

Recent findings: Schizophrenia and schizoaffective disorder lead to significant cognitive impairment. It is thought that dopamine dysregulation is the culprit for the positive symptoms of schizophrenia and schizoaffective disorder. Similar to other second-generation antipsychotics, paliperidone has affinity for dopamine D2 and serotonin 5-HT2A receptors. Paliperidone was granted approval in the United States in 2006 to be used in the treatment of schizophrenia and in 2009 for schizoaffective disorder.

Summary: Schizophrenia and schizoaffective disorder have a large impact on cognitive impairment, positive symptoms and negative symptoms. Patients with either of these mental illnesses suffer from impairments in everyday life. Paliperidone has been shown to reduce symptoms of schizophrenia and schizoaffective disorder.

Keywords: antipsychotic agents; cognitive dysfunction; dopamine; family characteristics; paliperidone palmitate; psychotic disorders; serotonin.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflict of interest to report in this project.

References

    1. Gaebel W., Zielasek J. Schizophrenia in 2020: Trends in diagnosis and therapy. Psychiatry Clin. Neurosci. 2015;69:661–673. doi: 10.1111/pcn.12322. - DOI - PubMed
    1. Dufton I.H., Marshall R.E. Adolescent Forensic Psychiatry. Taylor and Francis; Oxfordshire, UK: 2004. Substance misuse; pp. 164–178.
    1. Wilson J.E., Nian H., Heckers S. The schizoaffective disorder diagnosis: A conundrum in the clinical setting. Eur. Arch. Psychiatry Clin. Neurosci. 2013;264:29–34. doi: 10.1007/s00406-013-0410-7. - DOI - PMC - PubMed
    1. Correll C.U. Understanding Schizoaffective Disorder: From psychobiology to psychosocial functioning. J. Clin. Psychiatry. 2010;71:8–13. doi: 10.4088/JCP.9096su1cc.02. - DOI - PubMed
    1. Amann B.L., Canales-Rodríguez E.J., Madre M., Radua J., Monte G., Alonso-Lana S., Landin-Romero R., Moreno-Alcázar A., Bonnin C.M., Sarró S., et al. Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder. Acta Psychiatr. Scand. 2015;133:23–33. doi: 10.1111/acps.12440. - DOI - PMC - PubMed